Article Text

Download PDFPDF

Protocol
Azithromycin as an add-on treatment for persistent uncontrolled asthma in adults: protocol of a systematic review and meta-analysis
  1. Wei Liu1,
  2. Wei Mu2,
  3. Huiting Zhang3,
  4. Jingbo Zhai4,
  5. Xiaodan Li5,
  6. Peng Guan6,
  7. Fu Lian1,
  8. Jihong Feng1,
  9. Shuangjiang Yu3,
  10. Xuepin Wang3,
  11. Jinhua Si7,
  12. Zengtao Sun8,
  13. Yuhong Huang2
  1. 1 Department of Respiratory Medicine, Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China
  2. 2 Department of Clinical Pharmacology, Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China
  3. 3 Graduate School, Tianjin University of Traditional Chinese Medicine, Tianjin, China
  4. 4 Institute of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, China
  5. 5 VIP Inpatient Ward, Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China
  6. 6 Department of Emergency Medicine, Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China
  7. 7 Library, Tianjin University of Traditional Chinese Medicine, Tianjin, China
  8. 8 Office of Hospital Management, Tianjin University of Traditional Chinese Medicine, Tianjin, China
  1. Correspondence to Dr Zengtao Sun; sunzengtaopro{at}163.com; Dr Yuhong Huang; hyh101{at}126.com

Abstract

Introduction Clinical management of asthma remains a public challenge. Despite standard treatment with inhaled corticosteroids (ICS) and long-acting beta-agonists (LABAs), asthma remains uncontrolled in a substantial number of chronic asthma patients who risk reduced lung function and severe exacerbations. Azithromycin could have add-on effects for these patients. This study is proposed to systematically evaluate the efficacy of azithromycin as an add-on treatment for adults with persistent uncontrolled symptomatic asthma.

Methods and analysis Two reviewers will perform a comprehensive search of PubMed, Embase, the Cochrane Central Register of Controlled Trials (CENTRAL) and four Chinese electronic databases including China National Knowledge Infrastructure (CNKI), Chinese Biomedical Literature Database (CBM), WanFang Data and VIP Database from inception to May 2019. Only randomised controlled trials will be included. There is no restriction on language or publication status. Combined oral azithromycin and an ICS or/and a LABA will be compared with standard treatment alone or with a placebo. The primary outcomes are the number or frequency of asthma exacerbations, changes in asthma symptoms and lung function. Secondary outcomes include the number or frequency of inhalations of beta-agonists with or without corticosteroids for rescue use, eosinophil counts in blood or sputum, adverse events and others. A meta-analysis will be attempted to provide an estimate of the pooled treatment effect. Otherwise, qualitative descriptions of individual studies will be given.

Ethics and dissemination Ethical approval is not required because no primary data will be collected. Study findings will be presented at scientific conferences or published in a peer-reviewed journal.

PROSPERO registration number CRD42019117272.

  • azithromycin
  • asthma
  • systematic review protocol
  • add-on treatment
http://creativecommons.org/licenses/by-nc/4.0/

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

View Full Text

Statistics from Altmetric.com

Footnotes

  • WL and WM contributed equally.

  • Contributors WL and WM conceived the study and designed the protocol. WL, WM, HZ and JZ drafted the manuscript. WM and HZ developed the search strategy. JS revised the search strategy and adapted searches across different electronic databases. XL, PG, FL, JF, SY and XW provided general guidance to the development of the protocol and critically revised the manuscript. ZS and YH reviewed and revised the manuscript for important intellectual content. All authors read and approved the final manuscript.

  • Funding This work was supported by the National Natural Science Foundation of China grant numbers 81603447 and 81603495.

  • Disclaimer The funding agency plays no role in protocol development or in the decision to publish.

  • Competing interests None declared.

  • Patient consent for publication Not required.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.